Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial

IMPORTANCE: Preclinical data suggest that poly(ADP-ribose) polymerase (PARP) inhibitors have synergistic activity when combined with immune checkpoint inhibitors (ICIs); however, it is unknown which tumor types or molecular subtypes may benefit from this combination. OBJECTIVE: To investigate respon...

Descripción completa

Detalles Bibliográficos
Autores principales: Yap, Timothy A., Bardia, Aditya, Dvorkin, Michael, Galsky, Matthew D., Beck, J. Thaddeus, Wise, David R., Karyakin, Oleg, Rubovszky, Gábor, Kislov, Nikolay, Rohrberg, Kristoffer, Joy, Anil Abraham, Telli, Melinda L., Schram, Alison M., Conte, Umberto, Chappey, Colombe, Stewart, Ross, Stypinski, Daria, Michelon, Elisabete, Cesari, Rossano, Konstantinopoulos, Panagiotis A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673022/
https://www.ncbi.nlm.nih.gov/pubmed/36394849
http://dx.doi.org/10.1001/jamaoncol.2022.5228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673022/
https://www.ncbi.nlm.nih.gov/pubmed/36394849
http://dx.doi.org/10.1001/jamaoncol.2022.5228

Ejemplares similares